EP1809603A4 - NITROBENZINDOLES AND THEIR USE IN CANCER THERAPY - Google Patents

NITROBENZINDOLES AND THEIR USE IN CANCER THERAPY

Info

Publication number
EP1809603A4
EP1809603A4 EP05800725A EP05800725A EP1809603A4 EP 1809603 A4 EP1809603 A4 EP 1809603A4 EP 05800725 A EP05800725 A EP 05800725A EP 05800725 A EP05800725 A EP 05800725A EP 1809603 A4 EP1809603 A4 EP 1809603A4
Authority
EP
European Patent Office
Prior art keywords
nitrobenzindoles
cancer therapy
cancer
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05800725A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1809603A1 (en
Inventor
William Alexander Denny
William Robert Wilson
Ralph James Stevenson
Moana Tercel
Graham John Atwell
Shangjin Yang
Adam Vorn Patterson
Frederik Bastiaan Pruijn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Auckland Uniservices Ltd
Original Assignee
Auckland Uniservices Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auckland Uniservices Ltd filed Critical Auckland Uniservices Ltd
Publication of EP1809603A1 publication Critical patent/EP1809603A1/en
Publication of EP1809603A4 publication Critical patent/EP1809603A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
EP05800725A 2004-10-22 2005-10-21 NITROBENZINDOLES AND THEIR USE IN CANCER THERAPY Withdrawn EP1809603A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ536107A NZ536107A (en) 2004-10-22 2004-10-22 Nitrobenzindoles and their use in cancer therapy
PCT/NZ2005/000278 WO2006043839A1 (en) 2004-10-22 2005-10-21 Nitrobenzindoles and their use in cancer therapy

Publications (2)

Publication Number Publication Date
EP1809603A1 EP1809603A1 (en) 2007-07-25
EP1809603A4 true EP1809603A4 (en) 2009-09-02

Family

ID=36203204

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05800725A Withdrawn EP1809603A4 (en) 2004-10-22 2005-10-21 NITROBENZINDOLES AND THEIR USE IN CANCER THERAPY

Country Status (14)

Country Link
US (1) US7718688B2 (enExample)
EP (1) EP1809603A4 (enExample)
JP (1) JP2008517905A (enExample)
KR (1) KR20070083806A (enExample)
CN (1) CN101044114B (enExample)
AU (1) AU2005296389B2 (enExample)
BR (1) BRPI0517285A (enExample)
CA (1) CA2584702A1 (enExample)
IL (1) IL182652A0 (enExample)
MX (1) MX2007004596A (enExample)
NZ (1) NZ536107A (enExample)
RU (1) RU2007118938A (enExample)
WO (1) WO2006043839A1 (enExample)
ZA (1) ZA200703699B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008009956A (es) 2006-02-02 2008-12-12 Syntarga Bv Analogos de cc-1065 solubles en agua y sus conjugados.
US9901567B2 (en) 2007-08-01 2018-02-27 Syntarga B.V. Substituted CC-1065 analogs and their conjugates
US8076491B2 (en) 2007-08-21 2011-12-13 Senomyx, Inc. Compounds that inhibit (block) bitter taste in composition and use thereof
AU2008289485B2 (en) 2007-08-21 2014-08-14 Senomyx, Inc. Human T2R bitterness receptors and uses thereof
NZ571028A (en) * 2008-09-03 2011-01-28 Auckland Uniservices Ltd Nitrobenzindole compounds and their use in cancer treatment
NO2344478T3 (enExample) * 2008-11-03 2018-02-24
MX374267B (es) 2010-04-21 2025-03-06 Syntarga Bv Conjugados novedosos de analogos cc-1065 y ligaduras bifuncionales.
CN102827061A (zh) * 2012-09-19 2012-12-19 兰州大学 5,6,7-三甲氧基吲哚类衍生物、制备方法及用途
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
SG10201911860VA (en) 2014-01-10 2020-02-27 Synthon Biopharmaceuticals Bv Duocarmycin adcs showing improved in vivo antitumor activity
KR20160099725A (ko) 2014-01-10 2016-08-22 신톤 바이오파머슈티칼즈 비.브이. 자궁내막암의 치료에서 사용하기 위한 듀오카르마이신 adc
MX373458B (es) 2014-01-10 2020-05-11 Byondis Bv Metodo para purificar conjugados de anticuerpo-farmaco enlazados a cisteina.
AU2015282627B2 (en) 2014-06-30 2020-04-02 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
JPWO2019004413A1 (ja) * 2017-06-30 2020-05-07 東レ株式会社 インドリン誘導体及びそれを含む細胞毒性剤
CN112724068A (zh) * 2020-12-30 2021-04-30 蔡桂坡 具有hdac抑制活性的吲哚类衍生物的合成方法及肿瘤应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998011101A2 (en) * 1996-09-12 1998-03-19 Cancer Research Campaign Technology Limited Condensed n-aclyindoles as antitumor agents
WO2003097635A1 (en) * 2002-05-17 2003-11-27 Auckland Uniservices Limited Processes for preparing 3-substituted 1-(chloromethyl)-1,2-dihydro-3h-[ring fused indol-5-yl(amine-derived)] compounds and analogues thereof, and to products obtained therefrom

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192977B2 (en) * 2001-02-22 2007-03-20 School Of Pharmacy Benz-indole and benzo-quinoline derivatives as prodrugs for tumor treatment
NZ529249A (en) 2003-10-31 2006-04-28 Auckland Uniservices Ltd Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998011101A2 (en) * 1996-09-12 1998-03-19 Cancer Research Campaign Technology Limited Condensed n-aclyindoles as antitumor agents
WO2003097635A1 (en) * 2002-05-17 2003-11-27 Auckland Uniservices Limited Processes for preparing 3-substituted 1-(chloromethyl)-1,2-dihydro-3h-[ring fused indol-5-yl(amine-derived)] compounds and analogues thereof, and to products obtained therefrom

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ATWELL G J ET AL: "Synthesis and cytotoxicity of amino analogues of the potent DNA alkylating agent seco-CBI-TMI", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 7, no. 12, 17 June 1997 (1997-06-17), pages 1493 - 1496, XP004136243, ISSN: 0960-894X *
See also references of WO2006043839A1 *

Also Published As

Publication number Publication date
CN101044114B (zh) 2012-02-15
CA2584702A1 (en) 2006-04-27
AU2005296389A1 (en) 2006-04-27
US7718688B2 (en) 2010-05-18
NZ536107A (en) 2007-06-29
RU2007118938A (ru) 2008-11-27
EP1809603A1 (en) 2007-07-25
BRPI0517285A (pt) 2008-10-07
US20080119442A1 (en) 2008-05-22
KR20070083806A (ko) 2007-08-24
CN101044114A (zh) 2007-09-26
AU2005296389B2 (en) 2012-03-15
WO2006043839A1 (en) 2006-04-27
MX2007004596A (es) 2007-06-22
JP2008517905A (ja) 2008-05-29
IL182652A0 (en) 2007-07-24
ZA200703699B (en) 2008-10-29

Similar Documents

Publication Publication Date Title
ZA200703699B (en) Nitrobenzindoles and their use in cancer therapy
IL178012A0 (en) Diphenyl-indol-2-on compounds and their use in the treatment of cancer
EP2038041A4 (en) THERAPEUTIC COMPOUNDS AND THEIR USE AGAINST CANCER
TWI349551B (en) Thiophenepyrimidinone derivatives and their use in therapy
IL174994A0 (en) Pyrimidin - 4 - yl - 3, 4 - thione compounds and their use in therapy
AU2003293376A8 (en) Anti-angiogenic compounds and their use in cancer treatment
PL2287195T3 (pl) Przeciwciała pan-kir2dl receptora nk i ich zastosowanie w diagnostyce i terapii
SI1824855T1 (sl) Novi pirolo derivati d pirimidin ona in njihova uporaba pri zdravljenju
IL181608A0 (en) Cancer combination therapy comprising azd2171 and imatinib
GB0702696D0 (en) Porphyrin derivatives and their use in photon activation therapy
GB0418328D0 (en) Cancer methods and medicaments
TWI350286B (en) Alkylpiperazine- and alkylhomopiperazine-carboxylate derivatives, their preparation and their application in therapy
IL172826A0 (en) Quinoline derivates and their use in therapy
GB0523576D0 (en) Drug composition and its use in therapy
ZA200702093B (en) Arene ruthenium (II) compounds and their use in cancer therapy
EP1756166A4 (en) DIAGNOSIS AND TREATMENT OF PROSTATE CANCER
ZA200709542B (en) Combination therapy in the treatment of cancer
EP1838288A4 (en) THERAPEUTIC MATERIALS AND METHODS
GB0428170D0 (en) Mono and Combination Therapy
GB0326578D0 (en) Cancer diagnosis and therapy
IL164467A0 (en) binding agents and their use in targeting tumor cells
GB0407382D0 (en) Therapeutic methods and means
SI1639013T1 (sl) Pan-kir2dl nk-receptorska protitelesca in njihova uporaba pri diagnosticiranju in terapiji
IL185575A0 (en) Benzoxazocines and their therapeutic use
GB0700827D0 (en) Hai-1 and Hai-2 in cancer therapy

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070516

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

A4 Supplementary search report drawn up and despatched

Effective date: 20090731

17Q First examination report despatched

Effective date: 20091118

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130710